2月25日，复星医药（600196/02196）发布公告，控股子公司复星医药产业近日收到国家药监局关于同意复迈宁®联合安罗替尼用于鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌患者开展临床试验的批准。复星医药产业计划在条件具备后于中国境内开展该药品的Ⅱ期临床试验。
该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。截至2026年1月，该药品的累计研发投入约为6.68亿元（未经审计）。目前，该药品已在中国境内上市并获批两项适应症，同时还有两项适应症的药品上市申请已获国家药监局受理并纳入优先审评程序。根据IQVIAMIDAS最新数据，预计2024年MEK1/2选择性抑制剂的全球销售额约为20.68亿美元。
2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.